Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 progesterone infusion for severe traumatic brain injury
NL-OMON38198Phase 3Active, not recruiting
- Sponsor
- BHR Pharmaceuticals
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in traumatic brain injury (TBI) comparing BHR-100 intravenous infusion with Placebo intravenous infusion (2 arms). Primary endpoint: Glasgow Outcome Scale at 6 months. Started Mar 2011; status: active, not recruiting.
02
Drugs
BHR-100
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NL-OMON38198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38198.